NR3C2 and metabolic syndrome: Shifting our attention on patients with metabolic syndrome, Derosa et al. have shown that MR antagonism with canrenone significantly decreases fasting plasma insulin and improved HOMA-IR index, a widely used marker of insulin resistance [100].